Movement Alert｜AKESO Declines 3.07% in Regular Trading, Pullback After Previous Session Surge of Nearly 9%

Market Focus

Sep 22

On September 22, AKESO declined 3.07% in regular trading, trading at approximately 96.5 HKD/share, with turnover of approximately 174 million HKD. The retreat comes after the stock surged over 8.9% in the prior session amid a sector-wide rally in innovative drug stocks.

The previous session's spike was driven by two catalysts: reports that the US may ease licensing cooperation restrictions for pharmaceutical companies, boosting sentiment around cross-border biotech deal-making, and sustained momentum from the World Conference on Lung Cancer where AKESO's ivonescimab (AK112) HARMONi-2 study reported statistically significant overall survival results. Data showed median OS of 30.8 months for the ivonescimab arm versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73. Multiple investment banks including CITIC, Jefferies, Citi, and J.P. Morgan maintained buy or outperform ratings, with target prices ranging from 125 to 226 HKD.

Following concentrated release of positive catalysts and rapid share price appreciation, today's decline reflects partial profit-taking after the sharp short-term gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1186652877"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186652877\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186652877?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186652877","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AKESO Declines 3.07% in Regular Trading, Pullback After Previous Session Surge of Nearly 9%","media":"Market Focus","content":"<p><p>On September 22, AKESO declined 3.07% in regular trading, trading at approximately 96.5 HKD/share, with turnover of approximately 174 million HKD. The retreat comes after the stock surged over 8.9% in the prior session amid a sector-wide rally in innovative drug stocks.</p><p>The previous session's spike was driven by two catalysts: reports that the US may ease licensing cooperation restrictions for pharmaceutical companies, boosting sentiment around cross-border biotech deal-making, and sustained momentum from the World Conference on Lung Cancer where AKESO's ivonescimab (AK112) HARMONi-2 study reported statistically significant overall survival results. Data showed median OS of 30.8 months for the ivonescimab arm versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73. Multiple investment banks including CITIC, Jefferies, Citi, and J.P. Morgan maintained buy or outperform ratings, with target prices ranging from 125 to 226 HKD.</p><p>Following concentrated release of positive catalysts and rapid share price appreciation, today's decline reflects partial profit-taking after the sharp short-term gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Declines 3.07% in Regular Trading, Pullback After Previous Session Surge of Nearly 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Declines 3.07% in Regular Trading, Pullback After Previous Session Surge of Nearly 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-22 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 22, AKESO declined 3.07% in regular trading, trading at approximately 96.5 HKD/share, with turnover of approximately 174 million HKD. The retreat comes after the stock surged over 8.9% in the prior session amid a sector-wide rally in innovative drug stocks.</p><p>The previous session's spike was driven by two catalysts: reports that the US may ease licensing cooperation restrictions for pharmaceutical companies, boosting sentiment around cross-border biotech deal-making, and sustained momentum from the World Conference on Lung Cancer where AKESO's ivonescimab (AK112) HARMONi-2 study reported statistically significant overall survival results. Data showed median OS of 30.8 months for the ivonescimab arm versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73. Multiple investment banks including CITIC, Jefferies, Citi, and J.P. Morgan maintained buy or outperform ratings, with target prices ranging from 125 to 226 HKD.</p><p>Following concentrated release of positive catalysts and rapid share price appreciation, today's decline reflects partial profit-taking after the sharp short-term gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1186652877","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186652877","pubTimestamp":1790041320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 22, AKESO declined 3.07% in regular trading, trading at approximately 96.5 HKD/share, with turnover of approximately 174 million HKD. The retreat comes after the stock surged over 8.9%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势警报|AKESO 在常规交易中下跌 3.07%，前一交易日飙升近 9% 后回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On September 22, AKESO declined 3.07% in regular trading, trading at approximately 96.5 HKD/share, with turnover of approximately 174 million HKD. The retreat comes after the stock surged over 8.9% in the prior session amid a sector-wide rally in innovative drug stocks.The previous session's spike was driven by two catalysts: reports that the US may ease licensing cooperation restrictions for pharmaceutical companies, boosting sentiment around cross-border biotech deal-making, and sustained momentum from the World Conference on Lung Cancer where AKESO's ivonescimab (AK112) HARMONi-2 study reported statistically significant overall survival results. Data showed median OS of 30.8 months for the ivonescimab arm versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73. Multiple investment banks including CITIC, Jefferies, Citi, and J.P. Morgan maintained buy or outperform ratings, with target prices ranging from 125 to 226 HKD.Following concentrated release of positive catalysts and rapid share price appreciation, today's decline reflects partial profit-taking after the sharp short-term gains.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}